Erythropoietic response to hypoxaemia in diffuse idiopathic pulmonary fibrosis, as opposed to chronic obstructive pulmonary disease  by TASSIOPOULOS, S. et al.
Erythropoietic response to hypoxaemia in
diffuse idiopathic pulmonary fibrosis, as opposed to
chronic obstructive pulmonary disease
S. TASSIOPOULOS*, A. KONTOS*, K. KONSTANTOPOULOS*, C. HADZISTAVROU{, G. VAIOPOULOS*,
A. AESSOPOS* AND T. TASSIOPOULOS*
*First Department of Internal Medicine, Laikon Hospital, Athens and {Department of Chest Medicine, Chest
Diseases Hospital, Athens, Greece
The aim of this study was to assess the erythropoietic response to hypoxaemia in patients with diffuse idiopathic
pulmonary fibrosis (DIPF), and to speculate on the underlying mechanisms.
Patients on an established chronic respiratory failure due to DIPF or chronic obstructive pulmonary disease
(COPD) were studied. The erythropoietic response to hypoxaemia in both conditions was assessed. We studied 18
patients with DIPF and 29 patients with COPD in respiratory failure in a stable stage, free from acute infection and
congestive heart failure. Blood gases, erythrocytic parameters, as well the serum levels of iron, ferritin and
erythropoietin were determined.
All the DIPF patients studied, apart from two, had normal or subnormal haematocrit values. The patients with
COPD had an inconsistant response to hypoxaemia; 12 had normal or subnormal haematocrit values and the
remaining 17 were erythraemic. The mean value of erythropoietin (EPO) in both DIPF and COPD patients was
significantly higher than normal.
In conclusion, patients with DIPF exhibit a lack of erythropoietic response to hypoxaemia, despite the
augmented erythropoietin levels. This may reflect a defective bone marrow erythropoietic response in DIPF
patients. It is suggested that the pathophysiology of DIPF underlies this mechanism.
Key words: diffuse idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; erythrocytosis;
erythropoietin.
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Studies on erythropoietic response to hypoxaemia in
diffuse idiopathic pulmonary fibrosis (DIPF) are rather
limited. There is some evidence, to some extent an-
ecdotal, that hypoxaemia caused by DIPF is not usually
accompanied by secondary erythrocytosis (1–3). On the
other hand, according to a recent publication, 62% of
DIPF cases with hypoxaemia developed secondary
erythrocytosis (4).
We investigated this topic in an attempt: (i) to delineate
this conflicting information and (ii) to study the factors
governing erythropoietic response to hypoxaemia in DIPF
patients.Received 4 August 2000 and accepted in revised form 5 March
2001.
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0954-6111/01/060471+05 $35?00/0Materials and methods
We studied 47 consecutive patients, 18 with DIPF
(eight males, 10 females, aged 38–71 years: group A) and
29 with a diagnosis of classical chronic obstructive
pulmonary disease (COPD) (18 males, 11 females, aged
48–85 years: group B).
DIPF diagnosis is based on medical history, clinical and
imaging data (chest X-ray and high resolution computer-
ized tomography), and spirometry indicating severe con-
strictive syndrome. Diagnosis was confirmed with an open
lung biopsy. Secondary interstitial fibrosis was excluded by
clinical and laboratory investigation.
All our subjects were recruited in the Day Lung Clinic.
The selected DIPF or COPD patients fulfilled the following
criteria: (i) standing respiratory failure (PO2560mmHg)
for at least 6 months; (ii) non-aggressive status of their
disease (stable clinical condition and blood gases); (iii) no
history of infection for at least 6 months; (iv) no renal or
hepatic function derangement; no congestive heart failure,
no diabetes mellitus; (v) no use of steroids, diuretics,# 2001 HARCOURT PUBLISHERS LTD
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parameters for the last 12 months. Subjects in this study
were treated with some of these drugs in the past, but they
were discontinued due to lack of response.
It should be noted that no patient from those who
entered the study had smoked for the last year. However,
seven out of the 18 patients with DIPF and 23 out of the 29
with COPD were smokers at a variable severity. Informed
consent was given by all patients.
The resting arterial blood gases and the pH measure-
ments were performed with the Ciba-Corning 288 Blood
Gas System (Ciba Corning Diagnostic Corp., MA, U.S.A.).
A sitting sample from the radial artery was used. The blood
gases were not found to deviate from those in each patient’s
record during the last 3 months. Blood parameters
(haemocit, haemogloblin, red blood cells, red cell
indices) were measured by Coulter STKS analyser
(Beckman Coulter Inc., CA, U.S.A.) and serum iron and
ferritin levels by Hitachi 911 Autoanalyser (Hitachi,
Japan). Serum levels of erythropoietin (EPO) were deter-
mined by EPO TracTM 125J RIA kit (Incstar Corp,
Stilwater, MN, U.S.A.). For every case, sampling was
conducted in the morning (8:00–9:00 hours). Measurements
were made separately. For the statistical analysis we
applied the t-test for independent samples (two-sided test;
significance level 5%) and multiple regression analysis
(software package ‘Statistic for Windows version 4?3,’
StatSoft, Inc. 1993).TABLE 1. Patient characteristics and results of this study
DIPF (Group A)
Subjects n=18
M: 8
F: 10
Age (years) 57?56+11?59
PO2 (mmHg) 48?28+6?34
M: 47?50+3?42
F: 48?90+8?11
PCO2 (mmHg) 40?94+7?50
M: 36?25+3?96
F: 44?70+7?67
Haemocrit (%) M: 43?50+2?92
F: 41?11+3?48
Haemoglobin (g dl71) M: 13?85+0?79
F: 13?06+1?08
Red blood cells (6106ml71) M: 4?69+0?71
F: 4?29+0?34
MCV (fl) 95?22+8?76
Iron (mg dl71) 75?11+38?60
Ferritin (ng dl71) 129?38+111?20
EPO (mUml71) 20?46+8?33
M: 21?10+8?33
F: 19?94+8?74
Values refer to mean+SD. M: males; F: females; NS: statisticalResults
The two groups differ as far as mean age and sex ratio is
concerned. Due to the known gender difference as regards
erythrocyte parameters, the two groups were compared
after being subdivided according to sex (Table 1).
The hypoxaemia in all our cases was not statistically
different between groups A and B (mean PO2+SD:
48?28+6?34 vs. 50?90+6?99 mmHg; P=0?203). Hypercap-
nia was found in three out of 18 patients with DIPF and in
15 out of 29 patients with COPD (mean PCO2+SD in
groups A and B was 40?94+7?50 and 48?78+14?96mmHg
respectively; P=0?022).
In group A (DIPF), nine out of the 18 patients had a
normal haematocrit, seven were anaemic despite the severe
and long-lasting hypoxaemia and only two (11?11%) were
erythraemic. In the 29 patients with COPD, and for the
same degree of hypoxaemia, a notable variation in
haematocrit was observed; in 12 haematocrit was normal
or subnormal, while in the remaining 17 (58?62%) it was at
the level of erythrocytosis. The cut-off haematocrit values
for the Greek population were those of the study by
Kaltsoya-Tassiopoulou et al.: 47?4+3?2 for men and
41?2+2?3 for women (5) [Table 2, Fig. 1(a) and (b)]. After
grouping subjects according to gender, a difference exists
between the haematocrit of DIPF and COPD patients. By
t-test analysis, the above difference was statistically
significant in both genders. Namely, in DIPF and COPDCOPD (Group B)
n=29
M: 18
F: 11
69?86+9?17 P=0?0002
50?90+6?99 NS
M: 50?67+6?99 NS
F: 51?27+7?31 NS
48?78+14?96 P=0?022
M: 48?03+16?13 P=0?008
F: 50?00+13?48 NS
M: 48?36+6?71 P=0?017
F: 47?47+6?25 P=0?011
M: 15?31+1?83 P=0?009
F: 14?76+1?92 P=0?023
M: 5?36+0?83 NS
F: 5?39+0?61 P=0?0001
89?57+6?84 P=0?017
80?68+16?7 P=0?442
89?10+38?2 P=0?079
19?70+12?73 NS
M: 16?29+8?70 NS
F: 25?27+16?43 NS
ly non-significant difference.
TABLE 2. Development of secondary erythrocytosis in DIPF
and COPD patients
DIPF (Group A) COPD (Group B)
Total 2/18 (11?11%) 17/29 (58?62%)
Males 0/8 (0%) 8/18 (44?44%)
Females 2/10 (20%) 9/11 (81?82%)
FIG 1. Haematocrit levels in relation to hypoxaemia in (a)
male patients and (b) female patients studied. Normal
values: (——) mean +2 SD(     ). DIPF patients (*),
COPD patients (~).
TABLE 3. Multiple regression analysis. Derived parameter
estimate (B) together with standard error (SE) for the
examination of haematocrit by a series of predicted
variables in the two genders
b SE b P-value
Group (DIPF/COPD) Male 6?39 2?99 0?045
Female 6?57 2?74 0?029
PO2 (mmHg) Male 70?38 0?23 0?111
Female 70?17 0?21 0?435
PCO2 (mmHg) Male 0?03 0?09 0?775
Female 70?02 0?15 0?915
EPO (mUml71) Male 0?13 0?16 0?415
Female 0?05 0?09 0?590
FIG 2. Relationship to erythropoietin level to PO2.
Normal values: (——), mean +2 SD (     ). Male DIPF
patients (*), female DIPF patients (*), male COPD
patients (~), female COPD patients (~).
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respectively; P=0?017. In females it was 41?11+3?48 and
47?47+6?25; P=0?011.
Using a gender stratified multiple regression analysis with
haematocrit as the dependent variable and DIPF/COPD
status, PO2, PCO2 and EPO as independent variables, it is
clear that DIPF/COPD status is the only significant
variable associated with the development of erythraemia
in both genders (P=0?045 in males and 0?029 in females)
(Table 3).
The level of erythropoietin (EPO) was highly variable
among patients (Fig. 2). Both mean values for EPO
(20?46+8?33 for group A and 19?70+12?73 for group B)were higher than the normal values for our laboratory
(P=0?002 and 0?046 respectively). The normal value
(12?84+2?47, range 5?5–17?38mUml71, CV 15?40%) for
our laboratory was obtained in a population sample of 15
volunteers (eight males and seven females, aged 30–75
years), apparently healthy with normal haematologic and
biochemical parameters.
Discussion
A notable finding of this study is the lack of erythrocytosis
in almost all DIPF cases, as opposed to COPD patients, a
considerable proportion of whom develop erythrocytosis
(17 out of 29). All DIPF patients apart from two, despite
severe and long-lasting hypoxaemia, had normal or
subnormal haematocrit values. The haematocrit value in
DIPF patients is so low that a significant elevation of
plasma volume is needed to masking an increase of
erythrocyte mass; besides, the plasma volume elevation
found by some in hypoxaemic chronic pulmonary disease
474 S. TASSIOPOULOS ET AL.(6,7) is not generally accepted (8,9). This lack of erythro-
cytosis in hypoxaemic DIPF patients is in agreement with
anecdotal literature data (1–3), a notable exception being
the paper by Perez-Padilla et al. (4). An obvious explana-
tion for the results of this paper does not exist, except that
the cases were also exposed to the hypoxaemic stress of
2240m altitude of Mexico City.
The data from our DIPF cases (group A), exclude all
trivial causes for a lack of erythropoietic response to
hypoxaemia, namely: iron deficiency, hypercapnia-induced
bone marrow suppression (only three out of 18 patients had
a slightly elevated PCO2), inhibition of erythropoiesis by
chronic infection (no evidence of infection for the last 6
months), follate or vitamin B12 deficiency (as indicated by
red cell indices) or failure of the EPO-producing system
(EPO levels were higher than normal). The scattered
individual EPO values and the relatively low values found
in some patients do not weaken this point because the
reaction of the system to a hypoxaemic stimulus does not
maintain a permanently high level of EPO (10). Further-
more, the hypothesis that a very severe and long-standing
hypoxaemia can lead to a less predictable erythropoietic
response (4,7) does not provide an explanation for our cases;
in fact, the files of our patients demonstrate that they never
had a high haematocrit during the course of their disease.
The comparative data from DIPF and COPD subjects
leads to interesting speculations. The literature on the
haematocrit changes in hypoxaemic COPD patients re-
mains controversial. Some authors suggest that the increase
in haematocrit or red cell mass is quantitatively analogous
to that in normal subjects living at high altitudes
(8,9,11,12); on the contrary, some others report a decreased
response or even non-response to hypoxia (7,13,14). Iron
deficiency (15), infections (16), increased PCO2 (17),
increased plasma volume (6), sleep apnoea (18) and
compensating mechanisms such as increase in cardiac
output (19) or increase in oxygen unloading (20), have
been incriminated for a differentiated erythropoietic re-
sponse in some COPD cases but they do not provide a
complete explanation for the whole phenomenon
(8,11,13,21,22). All our COPD patients have a severe,
stable and long-lasting hypoxaemia, so according to the
model of erythrocytosis developing in high altitude dwell-
ers, these COPD subjects ought to develop a notable
erythrocytosis even without the synergistic action of other
contributing factors like sleep apnoea. However, it is noted
that only 58?62% of them developed erythrocytosis. No
evident explanation is provided for the fact from this study
or literature.
All these considerations seem to produce the question:
can a common pathophysiological mechanism underlie the
lack of development of erythrocytosis in most DIPF and in
some patients with COPD? According to our data, one can
assume that the non-erythropoietic response in almost all
hypoxaemic DIPF cases can be attributed to a defective
bone marrow response, despite a high EPO level. This
finding needs further clarification. At this point, the
pathogenesis of DIPF permits some theoretical considera-
tions. The primary derangement of DIPF seems to be the
macrophage trigger, finally leading to interstitial fibrosis(3). Macrophage stimulation is well known to affect
erythropoiesis in diseases sharing macrophage activation,
such as rheumatoid arthritis. In this group of diseases
soluble factors secreted by macrophages suppress erythro-
poiesis, leading to anaemia (23). This mechanism may also
be implicated in DIPF. In this context, despite hypoxaemic
stimulus and subsequent rise in EPO levels, the erythro-
poietic response is downregulated by stimulated macro-
phage-secreted factor(s). Obviously, this hypothesis needs
more experimental data to back it up.
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